Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  United Continental Holdings, Inc.    UAL


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

United Continental : Heathrow's transatlantic carriers spearhead pre-departure testing study

12/01/2020 | 08:22am EST

Heathrow's transatlantic carriers spearhead pre-departure testing study.


UK's hub airport is working with its transatlantic carriers as they trial different testing regimes which could help safely re-build international routes

The independent trials will inform an industry-funded study - representing the biggest pre-departure study in the UK - and could pave the way for a universal pre-departure passenger testing model

The combined trials use Collinson and Swissport's testing facilities in Terminals 2 and 5

Study aims to use real-world data from four airlines to demonstrate pre-departure testing is a safe and effective alternative to quarantine and travel restrictions

The results of pre-departure testing trials carried out by four of Heathrow's transatlantic carriers - American Airlines, British Airways, United Airlines and Virgin Atlantic - will be brought together by a study commissioned by the airport to demonstrate the effectiveness of pre-departure testing for passengers on international routes. The final report will be shared with governments on both sides of the Atlantic.

The group study follows on from the Government's 'Test to Release' initiative, which from the 15th December, will give passengers the option to reduce their quarantine period from 14 days to five, providing they test negative for the virus. Whilst the aviation industry has welcomed 'Test to Release', it has been clear that the ultimate objective for passenger testing is a pre-departure regime, and the combined airline trials aim to make the case for this much needed solution. The study will be funded by Heathrow and seeks to provide a better understanding of how pre-departure testing could be used to safely eradicate the need for self-isolation on arrival.

Heathrow will have access to anonymised testing data generated by each of the separate pre-departure trials being conducted by participating airlines. Each trial is unique to each airline, but these variations will provide richer and more diverse data that will strengthen the study's conclusions. The cumulative results of the various tests will help the industry and governments to evaluate which pre-departure testing approach is practical and safe enough to replace quarantine and other travel restrictions.

The number and scale of the carriers involved makes this the largest pre-departures study in the UK. Specialist oversight will be provided by Oxera and Edge Health, who will author the study. Oxera and Edge Health have previously identified a lack of real-world pre-departures data on which to base analysis of the effectiveness of this type of testing model.

The combined trials will be entirely free of charge for passengers and take place on selected transatlantic routes. It is expected that the study will assess the effectiveness of PCR tests, LAMP and Lateral Flow Antigen devices, where used on each airline's trial routes. Some of the trials will make use of Collinson and Swissport's testing facilities in Heathrow'sTerminal 2 and Terminal 5, which were launched earlier this year. All participants will need to abide by the Government guidelines at the time of travel, such as the requirement that passengers arriving at Heathrow must self-isolate for 14 days or, from 15th December, for five days at which point a negative test result would release them from quarantine.

These pre-departure tests are already being used by some customers on flights from Heathrow to some of the UK's most popular routes for trade and travel, in an effort to safely restore the country's international connectivity. This year, it was announced that Heathrow had been over-taken by Paris Charles de Gaulle as the busiest airport in Europe, endangering the UK's connectivity with the rest of the world. North America is one of the few markets with which the UK has a trade surplus with - meaning that the UK exports more than it imports from it - and the USA alone accounts for a fifth of Heathrow's traffic, with 21 million passengers and GBP22bn of UK exports travelling from the airport to America in 2019. All of these credentials continue to be seriously impacted by COVID-19, but pre-departure testing as an alternative to any quarantine on arrival could provide a way to reboot these vital links.

Heathrow CEO, John Holland-Kaye, said: 'These trials will build on the Government's initial testing strategy, setting a standard for a safer and more comprehensive approach to passenger testing, that we hope will accelerate the return to travel as we once knew it. With Brexit imminent, we need to urgently find the most effective way to restore the UK's trading network and facilitate safe global travel, keeping Britain competitive as it leaves the EU.

British Airways' CEO, Sean Doyle, said: 'After the welcome news last week that the Government is reducing quarantine for travellers to five days, British Airways is pleased to be working closely with the team at Heathrow on trials between the US and London which will seek to demonstrate that a robust pre-departure testing regime will help fully re-open the skies and eliminate the need for quarantine.

'We stand with our colleagues at Heathrow and other UK airlines to ensure that together we do all we can to get Britain and the economy moving again.'

United Airlines' Senior Vice President and Chief Customer Officer, Toby Enqvist, said: 'We welcome this collaboration with Heathrow Airport Limited that demonstrates the value of pre-departure testing and the role it plays in opening international travel. United has overhauled our cleaning procedures to help ensure an even safer travel experience and testing continues to be a key component of our multi-layered approach to ensuring our customers' wellbeing.'

Shai Weiss, CEO, Virgin Atlantic said:

'Industry-led trials, like our own London Heathrow-Barbados testing pilot, build on existing evidence that an effective pre-departure testing regime can safely replace quarantine. Through close collaboration, trial results will add to the body of real-world evidence being aggregated by Heathrow in this landmark study.

We call on UK Government to move swiftly towards this model, in order to open up the skies, replace quarantine and boost consumer confidence. It will allow free movement of people and goods to resume, supporting the UK's economic recovery and protecting more than 500,000 jobs reliant on aviation. We hope that testing will also lead the way for US borders to open to UK travellers.'

Notes to Editors:

About the individual airline trials:

British Airways/ American Airlines /oneworld: Passengers booked on flights that are part of the trial (departing Dallas/Fort Worth, New York'sJohn F. Kennedy Airport and Los Angeles Airport) have the option to take a first RT-PCR test 72 hours before their flight, a LAMP test on arrival at Heathrow followed by a further RT-PCR test 72 hours after arrival. The first route was launched on 25th November. British Airways will also introduce trials on its flight from Miami from 9th December.

United: Passengers and crew on certain flights from Newark Liberty International Airport to Heathrow are required to take rapid Abbott ID now tests (a molecular rapid test) at the airport on departure. Launched on 16th November until 11th December.

Virgin Atlantic: Passengers on selected flights from Heathrow to Barbados, and onwards to Antigua and Grenada are requested to take a free 'lateral flow' antigen test at the airport before they fly (in addition to existing entry requirements of an RT-PCR test for Barbados, Antigua and Grenada). To launch from December 9th.

About Edge Health

Edge Health is a firm that specialises in helping organisations to deliver better health and care

outcomes by creating better analytics and insights from their data. This work ranges from

consultancy through to the development of bespoke data products.

Established in 2017, Edge Health is a firm composed of economists and data scientists who

have worked extensively with the NHS as well as local government, private and independent


About Oxera

Oxera is an economics consultancy that advises companies, policymakers, regulators and

lawyers on any economic issue connected with competition, finance or regulation. We have

been doing this for more than 35 years, gathering deep and wide-ranging knowledge in the

sectors we specialise in, such as Aviation. We have a reputation for credibility and integrity

among those we advise, and among key decision-makers, such as policymakers, regulators

and courts.

Previous Oxera and Edge Health report highlighting lack of pre-departures data:


(C) 2020 Electronic News Publishing, source ENP Newswire

01/25Equities End Mixed as Biden Faces Possible Bipartisan Resistance to $1.9 Tril..
01/25UNITED CONTINENTAL : Airlines Launches Travel-Ready Center Platform For COVID-19..
01/25XPRESSPA : to Open New XpresCheck COVID-19 Testing Facilities at George Bush, Ne..
01/25UNITED CONTINENTAL : Launches Industry-Exclusive Technology to Ease the Burden o..
01/25Alaska Air Group Says It Has Its First Boeing MAX Jet
01/25CEOs Confront Employees' Doubts on Covid-19 Vaccine
01/22SECTOR UPDATE : Consumer Stocks Experience Late Slump, Ending Near Break-Even Ma..
01/22MARKET CHATTER : United Airlines Offers Fresh Exit Deals for Employees
01/22Airline Stocks Lower as EU Leaders Eye Stricter Travel Restrictions
01/22STREET COLOR : United Airlines is Reportedly Seeking Employees To Accept Exit De..
More news
Financials (USD)
Sales 2020 15 396 M - -
Net income 2020 -6 789 M - -
Net Debt 2020 15 872 M - -
P/E ratio 2020 -1,67x
Yield 2020 0,02%
Capitalization 12 592 M 12 592 M -
EV / Sales 2020 1,85x
EV / Sales 2021 1,45x
Nbr of Employees 74 400
Free-Float 99,8%
Duration : Period :
United Continental Holdings, Inc. Technical Analysis Chart | UAL | US9100471096 | MarketScreener
Technical analysis trends UNITED CONTINENTAL HOLDINGS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 22
Average target price 46,62 $
Last Close Price 40,38 $
Spread / Highest target 53,5%
Spread / Average Target 15,5%
Spread / Lowest Target -20,8%
EPS Revisions
Managers and Directors
J. Scott Kirby Chief Executive Officer
Brett J. Hart President
Oscar Munoz Executive Chairman
Jonathan Roitman Chief Operations Officer & Executive VP
Gerald Laderman Chief Financial Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
DELTA AIR LINES, INC.-3.26%24 707
AIR CHINA LIMITED-11.64%13 888
ANA HOLDINGS INC.-1.93%10 120